Clinical Trials Browser

Phase 2 × Sarcoma, Kaposi × Everolimus × Clear all

NCT01412515 2026-06-04

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

Phase 2 Terminated

Sarcoma, Kaposi